Ownership Information: ATP Life Science Ventures, L.P.

ATP Life Science Ventures, L.P. (0001593440)

State location: NY | State of Inc.: E9 | Fiscal Year End: 1231

formerly: Apple Tree Partners IV, L.P. (until 2020-11-27)

Business Address
230 PARK AVENUE, SUITE 2800
NEW YORK NY 10169
212-468-5800

Mailing Address
230 PARK AVENUE, SUITE 2800
NEW YORK NY 10169

Ownership Reports for Issuers: (Click on issuer name to see other owners for the issuer, or CIK for issuer filings.)

Issuer	Filings	Transaction Date	Type of Owner
Akero Therapeutics, Inc.	0001744659	2021-06-28	10 percent owner
Stoke Therapeutics, Inc.	0001623526	2021-06-28	10 percent owner
Cerecor Inc. Current Name:Avalo Therapeutics, Inc.	0001534120	2015-10-14	director, 10 percent owner
Novus Therapeutics, Inc. Current Name:Avalo Therapeutics, Inc.	0001404281	2014-09-22	director, 10 percent owner
TITAN PHARMACEUTICALS INC	0000910267	2013-11-25	10 percent owner

Items 1 - 25

The information presented below contains only portions of the information presented in the referenced filing or filings.
You should consult the original filing for complete information. Hyperlinks to the forms are provided for your convenience.

Acquistion or Disposition	Transaction Date	Issuer	Form	Transaction Type	Direct or Indirect Ownership	Number of Securities Transacted	Number of Securities Owned	Line Number	Issuer CIK	Security Name
D	2021-06-28	Stoke Therapeutics, Inc.	4	J-Other	--D	17161713.0000	0.0000	1	0001623526	Common Stock
D	2021-06-28	Akero Therapeutics, Inc.	4	J-Other	--D	5830203.0000	0.0000	1	0001744659	Common Stock
A	2020-11-24	Stoke Therapeutics, Inc.	4	P-Purchase	--D	375000.0000	17161713.0000	1	0001623526	Common Stock
A	2020-07-10	Akero Therapeutics, Inc.	4	P-Purchase	--D	415000.0000	5830203.0000	1	0001744659	Common Stock
A	2019-06-24	Akero Therapeutics, Inc.	4	C-Conversion	--D	4228764.0000	4228764.0000	1	0001744659	Common Stock
A	2019-06-24	Akero Therapeutics, Inc.	4	C-Conversion	--D	286439.0000	4515203.0000	2	0001744659	Common Stock
A	2019-06-24	Akero Therapeutics, Inc.	4	P-Purchase	--D	900000.0000	5415203.0000	3	0001744659	Common Stock
D	2019-06-24	Akero Therapeutics, Inc.	4	C-Conversion	--D	13000000.0000	0.0000	4	0001744659	Series A Preferred Stock
D	2019-06-24	Akero Therapeutics, Inc.	4	C-Conversion	--D	880568.0000	0.0000	5	0001744659	Series B Preferred Stock
D	2019-06-21	Stoke Therapeutics, Inc.	4	C-Conversion	--D	2799910.0000	0.0000	7	0001623526	Series B Convertible Preferred Stock
D	2019-06-21	Stoke Therapeutics, Inc.	4	C-Conversion	--D	7617746.0000	0.0000	6	0001623526	Series A-2 Convertible Preferred Stock
D	2019-06-21	Stoke Therapeutics, Inc.	4	C-Conversion	--D	4980168.0000	0.0000	5	0001623526	Series A Convertible Preferred Stock
A	2019-06-21	Stoke Therapeutics, Inc.	4	P-Purchase	--D	1388889.0000	16786713.0000	4	0001623526	Common Stock
A	2019-06-21	Stoke Therapeutics, Inc.	4	C-Conversion	--D	2799910.0000	15397824.0000	3	0001623526	Common Stock
A	2019-06-21	Stoke Therapeutics, Inc.	4	C-Conversion	--D	7617746.0000	12597914.0000	2	0001623526	Common Stock
A	2019-06-21	Stoke Therapeutics, Inc.	4	C-Conversion	--D	4980168.0000	4980168.0000	1	0001623526	Common Stock
A	2015-10-20	Cerecor Inc.	4	C-Conversion	--D	595436.0000	595436.0000	1	0001534120	Common Stock
D	2015-10-20	Cerecor Inc.	4	C-Conversion	--D	16672224.0000	0.0000	2	0001534120	Series B Convertible Preferred Stock
-	-	Cerecor Inc.	3	-	--D			1	0001534120	Series B Convertible Preferred Stock
-	-	Stoke Therapeutics, Inc.	3	-	--D			3	0001623526	Series B Convertible Preferred Stock
-	-	Stoke Therapeutics, Inc.	3	-	--D			2	0001623526	Series A-2Convertible Preferred Stock
-	-	Stoke Therapeutics, Inc.	3	-	--D			1	0001623526	Series A Convertible Preferred Stock
-	-	Tokai Pharmaceuticals Inc	3	-	--D		125000.0000	1	0001404281	Common Stock
-	-	Akero Therapeutics, Inc.	3	-	--I			2	0001744659	Series B Preferred Stock
-	-	Akero Therapeutics, Inc.	3	-	--I			1	0001744659	Series A Preferred Stock

http://www.sec.gov/cgi-bin/own-disp

Modified: 04/22/2016